ASCO: Drug Combo Ups Progression-Free Survival for Metastatic Prostate Cancer

THURSDAY, June 8, 2023 -- For patients with metastatic castration-resistant prostate cancer (mCRPC), talazoparib plus enzalutamide results in improvement in radiographic progression-free survival (rPFS), according to a study published online June 4...